Keros Therapeutics Files Routine 8-K on Jan 3, 2024

Ticker: KROS · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1664710

Keros Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyKeros Therapeutics, Inc. (KROS)
Form Type8-K
Filed DateJan 3, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, 8-K

TL;DR

**KROS filed a standard 8-K, no major news.**

AI Summary

Keros Therapeutics, Inc. filed an 8-K on January 3, 2024, primarily to disclose information under Regulation FD and other events. This filing indicates that Keros Therapeutics, trading under the symbol KROS on The Nasdaq Stock Market LLC, is maintaining its compliance with SEC regulations. For investors, this matters because it signals routine corporate governance and transparency, without revealing any new material financial or operational developments that would significantly alter the company's valuation or outlook.

Why It Matters

This filing is a standard regulatory update, indicating Keros Therapeutics is adhering to disclosure requirements without presenting new material information that would immediately impact investment decisions.

Risk Assessment

Risk Level: low — This 8-K filing is routine and does not contain any information that introduces new risks or changes the company's risk profile.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate need to adjust their investment thesis based on new material information from this specific document. Further research into the company's core business and previous filings would be more impactful.

Key Players & Entities

  • Keros Therapeutics, Inc. (company) — the registrant filing the 8-K
  • January 3, 2024 (date) — date of earliest event reported and filing date
  • 001-39264 (other) — Commission File Number for Keros Therapeutics
  • KROS (other) — trading symbol for Keros Therapeutics
  • The Nasdaq Stock Market LLC (other) — exchange where Keros Therapeutics' common stock is registered

FAQ

What is the purpose of this 8-K filing by Keros Therapeutics, Inc.?

The 8-K filing by Keros Therapeutics, Inc. on January 3, 2024, is primarily for Regulation FD Disclosure and Other Events, as indicated in the 'ITEM INFORMATION' section of the filing.

When was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 3, 2024, as stated under 'Date of Report (Date of earliest event reported): January 3, 2024'.

What is the trading symbol and the exchange where Keros Therapeutics, Inc. common stock is registered?

Keros Therapeutics, Inc. common stock trades under the symbol KROS and is registered on The Nasdaq Stock Market LLC, as specified under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address and phone number of Keros Therapeutics, Inc.?

The business address for Keros Therapeutics, Inc. is 1050 Waltham Street, Suite 302, Lexington, Massachusetts, 02421, and their telephone number is (617) 314-6297, according to the filing.

Is Keros Therapeutics, Inc. considered an emerging growth company according to this filing?

The filing includes a checkbox 'Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:', but it does not explicitly state whether the registrant is an emerging growth company. The checkbox for 'emerging growth company' is not marked, implying it is not being specifically addressed or confirmed as such in this particular filing context.

Filing Stats: 652 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-03 08:04:23

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 3, 2024, Keros Therapeutics, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section. Such information and the accompanying Exhibit 99.1 are not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On January 3, 2024, the Company issued a press release announcing that it plans to develop KER-065, a novel ligand trap designed to bind to and inhibit TGF- ligands, including myostatin (GDF8) and activin A, for the treatment of obesity. The Company also announced that it commenced its randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065 in healthy volunteers. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation dated January 2024. 99.2 Press release dated January 3, 2024 . 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: January 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.